| [1] |
Mekhmandarov S,Sandbank J,Cohen M, et al. Technetium-99m-MIBI scintimammography in palpable and nonpalpable breast lesions[J].J Nucl Med,1998,39(1):86-91.
|
| [2] |
Melloul M,Paz A,Ohana G, et al. Double-phase 99Tc-sestamibi scintimmography and trans-scan in diagnosing breast cancer[J].J Nucl Med,1999,140(3):376-380.
|
| [3] |
Becherer A,Heibich T,Staudenherz A, et al. The diagnostic value of planar and SPECT scintimammography in different age groups[J].Nucl Med Commun,1997,18:710-718.
|
| [4] |
Maublant J,de Latour M,Mestas D, et al. Technetium-99msestamibi uptake in breast tumor and associated lymph nodes[J].J Nucl Med,1996,37:922-925.
|
| [5] |
Cordobes MD,Starzec A,Delmon-Moingeon L, et al. Technetium-99m-ses tamibi uptake by human benign and malignant breast tumor cells:Correlation with mdr gene expression[J].J Nucl Med,1996,37:286-289.
|
| [6] |
Yoon JH,Bom HS,Song HC, et al. Double-phase Tc-99m sestamibi scintimammography to assess angiogenesis and Pglycoprotein expression in patients with untreated breast cancer[J].Clin Nucl Med,1999,24(5):314-318.
|
| [7] |
Kao CH,Tsai SC,Liu TG, et al. P-glycoprotein and multidrug resistance-related protein expressions in relation to technetium 99m MIBI scintimammography findings[J].Cancer Res,2001,15(61):1412-1414.
|
| [8] |
Mansi L,Rambaldi PF,Procaccini E, et al. Scintimammography with 99Tcm-tetrofosmin in the diagnosis of breast cancer and lymph node metastases[J].Eur J Nucl Med,1996,23:932-939.
|
| [9] |
Akcay MN,Akin Y,Karabag B, et al. 9Tcm-tetrofosmin in breast carcinoma and axillary lymph node metastases:a comparative study with 99Tcm-MIBI[J].Clin Nucl Med,1997,22:832-834.
|
| [10] |
Rodrigues M,Chehne F,Kalinowska W, et al. Uptake of 9Tcm-MIBI and 99Tcm-tetrofosmin into malignant versus nonmalignant breast cell lines[J].J Nucl Med,2000,41:1495-1499.
|
| [11] |
AMANO S,Inoue T,Tomiyoshi K, et al. In vivo comparison of PET and SPECT radiopharmaceuticals in detecting breast cancer[J].J Nucl Med,1998.1424-1427.
|
| [12] |
Palmedo H,Bender H,Grüwald F, et al. Comparison of 18F-FDG PET and 99Tcm-MIBI scintimammography in the detection of breast tumours[J].Eur J Nucl Med,1997,24:1138-1145.
|
| [13] |
Inbriaco M,Vecchio SD,Riccardi A, et al. Scintimammography with 99Tcm-MIBI versus dynamic MRI for non-invasive characterization of breast masses[J].Eur J Nucl Med,2001,28:56-63.
|
| [14] |
Taillefer R. The role of 99mTc-sestamibi and other conventional radio-pharmaceuticals in breast cancer diagnosis[J].Semin Nucl Med,1999,29:22-23.
|
| [15] |
Khalkhali I,Cutrone J,Mena I, et al. Technetium-99m-sestamibi scintimammography of breast lesions:Clin and pathological follow-up[J].J Nucl Med,1995,36:1784-1789.
|
| [16] |
Buscombe JR,Cwikla JB,Holloway B, et al. Prediction of the usefulness of combined mammography and scintimammography in suspected primary breast cancer using ROC curves[J].J Nucl Med,2001,42:3-8.
|
| [17] |
Buffaz PD,Gauchez AS. Can tumour marker assays be a guide in the prescription of bone scan for breast and lung cancers?[J].Eur J Nucl Med,1999,26:8-11.
|